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Mucinous epithelial ovarian cancers (MOC) are clinically and morphologically distinct from the other histological subtypes of ovarian
cancer. To determine the genetic basis of MOC and to identify potential tumour markers, gene expression profiling of 49 primary
ovarian cancers of different histological subtypes was performed using a customised oligonucleotide microarray containing 459000
probesets. The results show that MOC express a genetic profile that both differs and overlaps with other subtypes of epithelial
ovarian cancer. Concordant with its histological phenotype, MOC express genes characteristic of mucinous carcinomas of varying
epithelial origin, including intestinal carcinomas. Differences in gene expression between MOC and other histological subtypes
of ovarian cancer were confirmed by RT–PCR and/or immunohistochemistry. In particular, galectin 4 (LGALS4) was highly and
specifically expressed in MOC, but expressed at lower levels in benign mucinous cysts and borderline (atypical proliferative) tumours,
supporting a malignant progression model of MOC. Hence LGALS4 may have application as an early and differential diagnostic
marker of MOC.
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Carcinomas arising from the epithelial cells of the ovary are the
fifth most common malignancy in women and the leading cause
of death from gynaecological cancers. Epithelial ovarian cancers
comprise a group of related but distinct carcinomas that likely
arise from a common epithelial cell type but develop via
differentiation pathways and differ in their clinical presentation
and aetiology. They are currently classified into different
histological subtypes (including serous, endometrioid, mucinous
and clear cell) based on their morphological resemblance to
normal epithelia in the gynaecological and intestinal tracts;
however the genetic basis underlying their divergence is poorly
understood.
The majority of mucinous ovarian cancers (MOC) are diagnosed
at an early stage, either as borderline (atypical proliferative)
tumours or low-grade carcinomas, and have an excellent prognosis
(Sherman et al, 2004). Although less common, advanced MOC is
associated with a very poor survival that surpasses the poor
prognosis for women with advanced stage serous ovarian cancer
(Sherman et al, 2004). Accumulating pathological and epidemio-
logical evidence supports a progression model of MOC, from
benign cysts to borderline tumours to invasive adenocarcinoma
(Feeley and Wells, 2001; Shih and Kurman, 2004). However, it can
be difficult to identify invasion which may only be focally present
and thus such tumours, particularly those of large size, must be
extensively sampled for accurate diagnosis (Riopel et al, 1999;
Lee and Young, 2003; Seidman et al, 2003; Ronnett et al, 2004).
Moreover, it can be very difficult to differentiate primary MOC
from secondary mucinous carcinomas from other sites, in
particular the gastrointestinal tract (Hart, 2005). Indeed it is
thought that many carcinomas diagnosed as primary mucinous
epithelial ovarian cancer are likely metastatic disease, and that the
true frequency of mucinous carcinoma arising in the ovary is o3%
of all ovarian carcinomas (Gilks, 2004; Seidman et al, 2004). Hence
early diagnosis and accurate classification of MOC, including the
ability to identify patients who are likely to progress to invasive
disease, is critical to patient prognosis and treatment (Hart, 2005).
The molecular basis of MOC, including the genetic events that
initiate the development of disease and those leading to malignant
progression, are largely unknown. One genetic abnormality
characteristic of MOC is a high frequency of mutations in KRAS,
thought to occur early in the development of MOC (Feeley and
Wells, 2001). Unlike serous ovarian carcinomas, mutations in
p53 are rarely observed in MOC (Shih and Kurman, 2004). In our
laboratory, we have successfully applied transcript profiling of
whole tissue as a screening tool to determine molecular changes
underlying cancer, which has led to the identification of several
potential markers for prostate, ovarian and pancreatic cancer
(Henshall et al, 2003a,b; Heinzelmann-Schwarz et al, 2004; Segara
et al, 2005). In the current study, we have determined the gene
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sexpression profiles of mucinous borderline tumours and MOC
using oligonucleotide microarrays representing over 90% of the
expressed human genome. By comparing the results to transcript
profiles of the other histological subtypes of ovarian cancer, we
aimed to determine the molecular basis of mucinous ovarian
tumours and to identify potential tumour markers. Following
validation of the transcript profiling results using RT–PCR
analysis on ovarian cancer extracts of varying histological
subtypes, we determined the protein expression of one such
candidate tumour marker, galectin 4 (LGALS4), in primary ovarian
tissue (normal surface epithelium, benign mucinous cysts,
mucinous borderline tumours and ovarian carcinomas) using
high-throughput immunohistochemistry based on tissue micro-
arrays.
MATERIALS AND METHODS
Tissue and clinicopathological data
Tissue specimens (fresh/frozen and formalin-fixed paraffin-
embedded samples) collected from patients undergoing primary
laparotomy at the Gynaecological Cancer Centre, Royal Hospital
for Women, Sydney, and the Royal North Shore Hospital, Sydney,
between 1990 and 2003 were included in this study following
informed consent and approval by the appropriate hospital
research ethics committee. The histological classification at
diagnosis was independently confirmed by a gynaecological
pathologist for all tissue specimens before inclusion in the study.
Normal ovaries were obtained from patients undergoing surgery
for benign gynaecological conditions or unrelated malignancies.
Patients exhibiting clinical, morphological or microscopic features
suggesting metastatic mucinous ovarian carcinoma rather than
primary MOC, including concurrent gastrointestinal carcinomas,
the presence of Pseudomyxoma peritonei/ovarii, bilateral disease,
Krukenberg tumours, and advanced stage borderline tumours (Lee
and Young, 2003; Seidman et al, 2003; Hart, 2005), were excluded
from the study. The clinical and pathological details of the tissue
cohort used in this study are shown in Table 1.
Molecular profiling and data analysis
Transcript profiling was performed as previously described
(Heinzelmann-Schwarz et al, 2004) using the Eos Hu03, a
customised Affymetrix GeneChip
s oligonucleotide microarray
containing over 59000 probesets for the interrogation of
approximately 46000 unique sequences (Eos Biotechnology/
Protein Design Labs, Fremont, CA, USA; Platzer et al, 2002) using
total RNA extracted from three MOC (stage I), four mucinous
borderline tumours, eight endometrioid ovarian cancers, 31 serous
ovarian cancers, three serous borderline tumours, and four normal
ovaries. Only those tumour samples containing 475% of border-
line or invasive cancer were used for transcript profiling. Following
normalisation as described (Henshall et al, 2003a), data was log-
transformed before further analysis. In addition, prior to
hierarchical clustering or principal components analysis, the data
were scaled to ensure that each gene exhibited the same mean
and variance. Principal components analysis was used to provide a
visual demonstration of the variation in gene expression of the top
ranked between ovarian cancer histological subtypes using the
Stats package in R (http://www.r-project.org; Smyth, 2004).
Hierarchical clustering of genes and samples was performed using
an euclidean distance metric with average linkage (Spotfire
DecisionSite 8.0).
A penalised t-test (Lo ¨nnstedt and Speed, 2002; Smyth, 2004) was
used to identify genes differentially regulated between MOC and
other subtypes of ovarian cancer. P-values were adjusted for
multiple testing using the Benjamini-Yekutieli method (Benjamini
and Yekutieli, 2001). Genes with an adjusted P-value o0.01 can be
interpreted as having a false discovery rate of 1%. Genes were
assigned to functional categories (molecular function, biochemical
process, cellular localisation, chromosome) using Gene Ontology
(http://vortex.cs.wayne.edu/projects.htm; Draghici et al, 2003) and
GenMAPP (www.genmapp.org) analysis (Dahlquist et al, 2002).
RT–PCR
RNA (2mg) was treated with DNAse then reverse-transcribed using
the Reverse Transcription System (Promega, Australia) according
to the manufacturer’s instructions. Semi-quantitative RT–PCR
was performed by the amplification of selected gene transcripts
using 2ml of the resulting cDNA in a 25ml reaction volume
incorporating 200mM of dNTPs (Roche, Australia), 2.5mM MgCl2,
1.5U of Amplitaq Gold (Promega), and 1mM of each oligonucleo-
tide pair. Oligonucleotide primers and PCR product size for each
gene were as follows: LGALS4: forward 50 GCTCAACGTGGG
AATGTCTGTTTAC, reverse 50 TTGTAGTGCTCAGCCAGGAC
TATG (260bp); MGC32871: TGAGTCACGGACTTGCAG,
TTCGCCACAAACAGTATCA (260bp); MUCDHL: AATGTGGAA
CCCAGCCACA, CACGTTTCCCCTAAAGATGCT (270bp); CDH17:
CTTCACTCCCTGTGTCTTCTTATGC, CCTGTCCAAGGCTCTGTT
GTAATAC (240bp); MEP1A: GGTTTCATCTCCCACCAAATGC,
AGGTACGGCTTCCTCTAACATGG (220bp); MUC13: GCATTTGG
CTACAGTGGACTCG, CTTAGGAAAGACGCTCCCTTCTG (240bp);
FABP1: GAGCCAGGAAAACTTTGAAGCC, TGGTGATTATGTCG
CCGTTGAG (300bp); C19orf21: CCAACGCCAGATGAGAACT,
Table 1 Clinical and pathological details of the ovarian tumour cohort
used for immunohistochemistry (n¼124)
a
Variable No. patients (%)
Histological type
Serous 55 (44.4)
Mucinous 39 (31.4)
Endometrioid 22 (17.7)
Clear cell 8 (6.5)
FIGO stage
b
I 27 (28.4)
II 5 (5.3)
III 55 (57.9)
IV 8 (8.4)
Grade
c
Borderline (mucinous only) 29 (24.8)
1 20 (17.1)
2 35 (29.9)
3 33 (28.2)
Age
o60 62 (50.0)
X60 62 (50.0)
Residual disease
p1 92 (74.2)
41 32 (25.8)
CA125
d
p500 58 (60.0)
4500 39 (40.0)
Outcome
c
Alive 62 (53.0)
Death (related to malignancy) 48 (41.0)
Death (unrelated or unknown cause) 7 (6.0)
aUnless otherwise stated.
bCarcinomas only; n¼95.
cn¼117.
dn¼97.
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sCGTTCTTGTGACGGGTC (260bp); MUC2: CGGTAAAACGACCC
CACACAAG, CATCAAAGCCAGGAGCGTAGTTC (400bp); TFF1:
TGGAGAACAAGGTGATCTGCG, AAACAGCAGCCCTTATTTGC
AC (160bp); REGIV: TATCAGAGAAGCCAGCCGATATG, TTGCA
CAGGAAGTGTTGGCG (200bp). Amplification of GAPDH
(GTCCACTGGCGTGTTCACCA, GTGGCAGTGATGGCATGGAC,
260bp) was used as a control. Cycling commenced with a 12min
heat activation at 951C, followed by 24 cycles of strand
denaturation at 951C for 30s, annealing at 55–601C for 30s, and
extension at 721C for 1min. A final extension time of 7min
followed the last cycle. Products were separated on a 2% agarose
gel in Tris-Acetate-EDTA buffer and visualised using ethidium
bromide staining.
Immunohistochemistry
Protein expression of LGALS4 was determined in a cohort of fixed
tissue from 124 patients with ovarian cancer (comprising 10 MOC
(independent of the samples that were transcript profiled), 55
serous ovarian cancers, 22 endometrioid ovarian cancers, eight
clear cell ovarian cancers, and 29 mucinous borderline tumours;
Table 1). In addition, eight benign mucinous cysts and 14 normal
ovaries, some of which contained inclusion cysts (sites of enclosed
metaplastic epithelium proposed as a precursor lesion for some
ovarian carcinomas; Feeley and Wells, 2001), were used for
immunohistochemistry. All tissues were incorporated into tissue
microarrays following pathological review, with each patient
represented by two to five tissue cores.
Tissue sections (4mm) were dewaxed and rehydrated according
to standard protocols, and endogenous peroxidase blocked using
3% H2O2. Sections were treated with proteinase K to facilitate
antigen retrieval, followed by incubation for 1h with goat anti-
galectin 4, 1:100 (sc19286, Santa Cruz Biotechnology, CA, USA).
Bound antibody was detected using the LSABþKit/HRP and
DABþ(diaminobenzidine) (DAKO Cytomation) and hematoxylin
counterstaining. A negative control omitted the primary antibody,
and a positive (small bowel) and negative (testis, skeletal muscle)
control tissue was included. Scoring was independently assessed by
two observers trained in gynaecological pathology and discrepan-
cies resolved by consensus. All cells within each core were counted
and the percentage of cells staining for each core determined. The
average percentage staining of multiple cores was calculated for
each patient. Box and whisker plots showing staining distributions
(median and 25th–75th percentile range) were produced using the
Base library in R (http://www.r-project.org). The median is marked
as a horizontal line between the box edges, which represent the
25th and 75th percentile values. The length of the whiskers is 1.5
times the interquartile range and values outside this range are
marked as circles. Differences in protein expression were
determined using the Mann–Whitney U-test, and correlations
between gene expression and clinicopathological parameters were
analysed using Fisher’s exact test. A P-value of p0.05 was required
for significance. All statistical analyses were performed using
Statview 4.5 software (Abacus Systems, Berkeley, CA, USA).
RESULTS
MOC exhibit a gene expression profile distinct from other
ovarian cancers
Principal components analysis on the top 500 most variable genes
identified by transcript profiling showed that MOC can be clearly
distinguished from the other subtypes of ovarian cancer by their
expression profile, and cluster more closely to endometrioid
ovarian cancer than to serous carcinomas (Figure 1A), as
previously observed (Schwartz et al, 2002; Hart, 2005). Using a
penalised t-statistic, we identified 167 probesets with higher
expression in MOC compared to serous and endometrioid ovarian
cancers (P-value adjusted for multiple testing o0.01) (Table 2 and
Supplementary Data), and 18 probesets whose expression was
lower in MOC compared to the other cancers (Supplementary
Data). Hierarchical clustering illustrated that these genes can
clearly separate MOC from the other subtypes of ovarian cancer,
and shows that in most cases mucinous borderline tumours cluster
closely with MOC (Figure 1B). Genes identified as having low
expression in MOC compared to the other subtypes had similar
expression levels in normal (whole) ovaries (Figure 1B), and their
identification here may reflect their high expression in serous/
endometrioid ovarian cancers rather than reduced expression in
MOC.
In all, 40 genes with higher expression in MOC compared to
normal ovaries were identified (Table 3). As the normal ovaries
were not microdissected before RNA extraction and profiling and
therefore contain a high proportion of stromal tissue compared to
epithelial cells, these genes likely reflect epithelial-specific genes
expressed in MOC. Nonetheless, the majority of these genes are
common to all subtypes of ovarian cancer, and several have been
previously implicated in its pathogenesis, including TACSTD1
(Ep-CAM), CDH1 (E-cadherin), KLF5 (Kruppel-like factor 5) and
ERB-B3 (Darai et al, 1997; Balzar et al, 1999; Maihle et al, 2002;
Heinzelmann-Schwarz et al, 2004). Combining the two analyses,
we identified that 13 of these 40 genes overlap with those that are
upregulated in MOC compared to the other subtypes of ovarian
cancer (highlighted in Table 3). Only four genes were identified as
down-regulated in MOC compared to normal ovaries (adjusted
Po0.01) (Table 3), all of which are also reduced in the other
subtypes of ovarian cancer.
We next clustered the upregulated genes in MOC compared to
the other subtypes by their chromosomal location and identified
several genomic regions that appeared to be over-represented in
MOC, including 3p21.3 (VILL, MST1R, SLC26A6, GLYCTK,
FLJ20209), 7q22 (MUC3B, ACHE, MUC17, CLDN15, LOC55971),
11p15 (USH1C, MUCDHL, MUC2, SLC22A18), 11q13 (STATD10,
PLCB3, MOGAT2), 11q24 (CTXL, KIAA1201, LOC120224, RICS),
15q14-15 (PPP1R14D, ITPKA, CKMT1, NMES1), 19p13.3 (FUT3,
FLEKHJ1, C19orf21, LOC284422, GNA11), 19q13.1-13.4 (CYP2S1,
FXYD3, LGALS4, CEACAM5, CEACAM6, FLJ20200. PTPRH), and
20q13 (HNF4A, BCAS1, PTK6). Chromosomes 11q24, 19q13.2, and
20q13 have been previously associated with a high frequency of
loss of heterozygosity in MOC (Feltmate et al, 2005). Together
these data suggest chromosomal amplification affecting these
genomic loci in MOC. Moreover, both 3p21.3 (MST1R) and 20q13
(PTK6) contain putative oncogenes (Barker et al, 1997; Hess et al,
2003; Maggiora et al, 2003; Wang et al, 2003), which are frequently
located in regions of genomic amplification in cancer.
Using RT–PCR, we determined the expression patterns of 11
selected genes in RNA extracts from whole normal ovaries,
mucinous borderline tumours and ovarian cancers (Figure 2).
All of the genes were confirmed as being upregulated in MOC
compared to serous ovarian cancer and/or normal ovaries.
MOC express genes associated with mucin production and
intestinal-type epithelium
Using Gene Ontology classifiers, we grouped the genes with
upregulated expression in MOC compared to the other subtypes to
identify biological processes that may specifically underlie the
development and progression of MOC. Consistent with its
morphological phenotype, we identified genes encoding several
mucins including MUC2, MUC3A (MUC3) and MUC17 but not
MUC16 (CA125). This mucin profile is similar to that of mucinous
colon carcinomas, in particular the presence of MUC2 and absence
of MUC5A (Byrd and Bresalier, 2004; Hart, 2005). Several mucin-
related molecules involved in carbohydrate metabolism and
protein glycosylation were identified including FUT3, GCNT3, SI,
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sFBP1, UGT1A9; and TFF1, an estrogen-regulated member of the
trefoil factor family of secreted peptides associated with mucin
production and frequently overexpressed in other mucinous
adenocarcinomas (Emami et al, 2004).
We also identified a number of genes associated with intestinal
expression including the caudal type homeobox transcription
factors CDX1 and CDX2. CDX transcription factors are essential
in intestinal epithelial development, and are also associated
with oncogenesis via the modulation of various cellular processes
including proliferation, apoptosis, and cell adhesion (Guo et al,
2004). Moreover, two CDX2 intestinal-specific targets were
identified: sucrase isomaltase (SI), a critical gene in intestinal
development (Guo et al, 2004) and CDH17, an enterocyte-specific
cell adhesion molecule (Hinoi et al, 2002). Other intestinal-type
cell adhesion molecules included LGALS4, a member of the
galectin family of carbohydrate-binding molecules (Huflejt and
Leffler, 2004); three members of the transmembrane 4 (tetra-
spanin) superfamily (TM4SF4/IL-TMP, TM4SF5/L6H and TM4SF3/
CO-029) associated with cellular proliferation, adhesion, motility,
and tumour cell metastasis (Wright et al, 2000); and two members
of the carcinoembryonic antigen family, CEACAM6 and CEACAM5
(CEA), frequently expressed by at least a subset of MOC
(McCluggage, 2000). The identification of intestinal-type adhesion
factors suggests that altered cell adhesion is a feature of MOC,
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Figure 1 (A) Principal components analysis based on 500 genes with the most variable signal intensities (based on variance) separates the histological
subtypes of EOC. MOC (n¼3) are circled; (B) Hierarchical clustering and heat map of differentially expressed genes (n¼167 upregulated and n¼18
down-regulated) in MOC compared to serous and endometrioid ovarian cancers. Clustering was performed on all transcript profiled samples (n¼3 MOC;
n¼4 mucinous borderline tumours; n¼8 endometrioid ovarian cancers (endo); n¼3 serous borderline tumours; n¼31 serous ovarian cancers (unlabelled
columns); and four normal ovaries) as described in the Materials and Methods. Expression levels are colour coded with red, green and black corresponding
to an increase, a decrease, and no change in gene expression, respectively.
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ssimilar to other histological subtypes of ovarian cancer (Heinzel-
mann-Schwarz et al, 2004). Moreover, several of these adhesion
factors have been previously implicated in carcinogenesis, includ-
ing TM4SF and CEACAM family members (Scholzel et al, 2000;
Wright et al, 2000; Ilantzis et al, 2002), CDH17 (Grotzinger et al,
2001; Takamura et al, 2004), and LGALS4 (Huflejt and Leffler,
2004).
Cellular pathways underlying MOC development
Gene Ontology analysis identified a number of genes involved in
cellular processes associated with cancer, including cell adhesion,
signalling, proliferation, and apoptosis (Table 4). Several putative
oncogenes were differentially expressed in MOC, including the
breast tumour kinase BRK (PTK6) (Barker et al, 1997) not
previously implicated in ovarian cancer pathogenesis; and MST1R/
RON, a receptor tyrosine kinase associated with proliferation and
motility of cancer cells including ovarian carcinoma (Hess et al,
2003; Maggiora et al, 2003; Wang et al, 2003).
Although KRAS mutations are associated with MOC (Shih and
Kurman, 2004), we did not find any evidence of increased KRAS
activity at the transcriptional level. Using GenMAPP analysis, we
examined if any probesets corresponding to other members of the
mitogen activated protein (MAP) kinase cascade were differentially
expressed in MOC compared to the other subtypes of ovarian
cancer. This revealed a slight increase in ERK1 (1.19-fold change,
Table 2 Genes (n¼50 of 167 probesets
a) identified as upregulated in MOC compared to other histological subtypes of ovarian cancer (ranked by
adjusted Po0.01)
Rank Symbol
b Name Unigene
c Locus link Location
1 LGALS4 Lectin, galactoside-binding, soluble, 4 (galectin 4) Hs.5302 3960 19q13.2
2 cDNA clone IMAGE:5759948, partial cds Hs.447537 NA 15q15.1
3 Hypothetical protein MGC32871 Hs.242014 119467 10q26.3
4 MUCDHL Mucin and cadherin-like Hs.165619 53841 11p15.5
5 apobec-1 complementation factor Hs.8349 29974 10q21.1
6 CDH17 Cadherin 17, LI cadherin (liver-intestine) Hs.89436 1015 8q22.1
7 MEP1A Meprin A, alpha (PABA peptide hydrolase) Hs.179704 4224 6p12-p11
8 MUC13 Mucin 13, epithelial transmembrane Hs.5940 56667 3q21
9 FABP1 Fatty acid binding protein 1, liver Hs.380135 2168 2p11
10 MUC3B Mucin 3B, intestinal Hs.489354 NA 7q22
11 CEACAM5 CEA-related cell adhesion molecule 5 (CEA) Hs.220529 1048 19q13.2
12 PDZK2 PDZ domain containing 2 Hs.374726 79849 11q23.3
13 GPA33 Glycoprotein A33 (transmembrane) Hs.437229 10223 1q24.1
14 RNF128 Ring finger protein 128 Hs.496542 79589 Xq22.3
15 MUCDHL Mucin and cadherin-like Hs.165619 53841 11p15.5
16 EPS8L3 EPS8-like 3 Hs.485352 79574 1p13.2
17 BCL2L14 BCL2-like 14 (apoptosis facilitator) Hs.504794 79370 12p13.2
18 SYTL2 Synaptotagmin-like 2, transcript variant a Hs.369520 54843 11q14.1
19 HMGCS2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial) Hs.59889 3158 1p13-p12
20 FAM3D Family with sequence similarity 3, member D Hs.61265 131177 3p21.2
21 MYO1A Myosin IA Hs.5394 4640 12q13.3
22 SLC26A3 Solute carrier family 26, member 3 Hs.1650 1811 7q31
23 ATP10B ATPase, Class V, type 10B Hs.109358 23120 5q34
24 BTNL8 Butyrophilin-like 8 Hs.189109 79908 5q35.3
25 MYO7B Myosin VIIB Hs.154578 4648 2q14.3
26 CDX1 Caudal type homeo box transcription factor 1 Hs.1545 1044 5q33.1
27 cDNA clone IMAGE:4661388, partial cds Hs.306721 400573 17p13.1
28 ESTs; moderate similarity to protein P39188 (H.sapiens) Hs.282795 NA 10q11.23
29 ESTs Hs.116462 NA 20q13.12
30 Cisplatin resistance associated Hs.425144 10903 1q21.2
31 TRIM31 Tripartite motif-containing 31 Hs.493275 11074 6p21.3
32 UGT1A9 UDP glycosyltransferase 1 family, polypeptide A9 Hs.124112 54600 2q37
33 ACHE Acetylcholinesterase (YT blood group) NA 43 7q22
34 PLA2G10 Phospholipase A2, group X Hs.144442 401831 16p13.1-p12
35 Hypothetical protein LOC144347 Hs.432901 144347 12q24.31
36 GUCY2C Guanylate cyclase 2C (heat stable enterotoxin receptor) Hs.524278 2984 12p12
37 cDNA clone IMAGE:4806358, partial cds Hs.328236 NA 4q32.3
38 PLAC8 Placenta-specific 8 Hs.371003 51316 4q21.3
39 KIAA0828 protein Hs.195058 23382 7q32.3
40 COL17A1 Collagen, type XVII, alpha 1 Hs.117938 1308 10q25.1
41 CLCA1 Chloride channel, calcium activated, family member 1 Hs.194659 1179 1p31-p22
42 Hypothetical protein FLJ20225 Hs.124835 54546 1p36.13
43 TM4SF4 Transmembrane 4 superfamily member 4 Hs.133527 7104 3q25
44 MUC17 mucin 17 Hs.271819 140453 7q22
45 FA2H Fatty acid 2-hydroxylase Hs.461329 79152 16q23
46 HNF4A Hepatocyte nuclear factor 4, alpha Hs.116462 3172 20q12-q13.1
47 SEMA4G Sema domain, immunoglobulin domain, transmembrane domain and short
cytoplasmic domain, (semaphorin) 4G
Hs.444359 57715 10q24.32
48 cDNA FLJ26898 fis, clone RCT00475 Hs.199371 NA 11q13.1
49 C9orf152 Chromosome 9 open reading frame 152 Hs.125608 401546 9q32
50 S100P S100 calcium binding protein P Hs.2962 6286 4p16
aFull list of genes are listed in Supplementary Data.
bHUGO.
cUnigene identifiers were derived from the UniGene Build #176 (October 2004).
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sunadjusted Po0.001) and a two-fold decrease in MAP kinase
kinase 1 (MEKK1) expression (0.61-fold change, unadjusted
P¼0.03), the latter being linked to cisplatin-resistance in
ovarian cancer (Gebauer et al, 2000), a feature of MOC (Hess
et al, 2004).
LGALS4 is specifically expressed in MOC
LGALS4 is an intestinal cell surface adhesion molecule that is
overexpressed in intestinal carcinomas (Grotzinger et al, 2001).
The results of the transcript profiling experiment suggested that
LGALS4 was also highly overexpressed in MOC (Table 2,
Table 3 Genes identified as (A) up-regulated (n¼40) and (B) down-regulated (n¼4) in MOC compared to normal ovaries (ranked by adjusted
Po0.01). Genes highlighted in bold (n¼13) are also up-regulated in MOC compared to other subtypes of ovarian cancer
Rank Symbol Name Unigene Locus Link Location
(A) Upregulated
1 LGALS4 Lectin, galactoside-binding, soluble, 4 (galectin 4) Hs.5302 3960 19q13.2
2 Hypothetical protein FLJ20171 Hs.487471 54845 8q22.1
3 TACSTD1 Tumor-associated calcium signal transducer 1 (Ep-CAM) Hs.692 4072 2p21
4 ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 Hs.306251 2065 12q13
5 cDNA clone IMAGE:5759948, partial cds Hs.447537 NA 15q15.1
6 BCMP11 Breast cancer membrane protein 11 Hs.100686 155465 7p21.1
7 CXXC5 CXXC finger 5 Hs.189119 51523 5q31.2
8 EHF Ets homologous factor Hs.502306 26298 11p12
9 STARD10 START domain containing 10 Hs.188606 10809 11q13
10 C19orf21 Chromosome 19 open reading frame 21 Hs.439180 126353 19p13.3
11 MUC13 Mucin 13, epithelial transmembrane Hs.5940 56667 3q21.2
12 PROM1 Prominin 1 Hs.479220 8842 4p15.32
13 MUCDHL Mucin and cadherin-like Hs.165619 53841 11p15.5
14 Hypothetical gene supported by BC022385; BC035868; BC048326 Hs.390599 440335 16p13.3
15 CEACAM5 Carcinoembryonic antigen-related cell adhesion molecule 5 (CEA) Hs.220529 1048 19q13.1-q13.2
16 AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 Hs.320151 10555 9q34.3
17 Hypothetical protein MGC32871 Hs.242014 119467 10q26.2
18 Hypothetical protein MGC11242 Hs.368260 79170 17q21.32
19 CLDN7 Claudin 7 Hs.513915 1366 17p13
20 FLJ46072 protein Hs.67776 286077 8q24.3
21 CALML4 Calmodulin-like 4; breast cancer antigen NY-BR-20 Hs.435457 91860 15q23
22 PLS1 Plastin 1 (I isoform) Hs.203637 5357 3q23
23 KLF5 Kruppel-like factor 5 (intestinal) Hs.508234 688 13q22.1
24 KIAA0101 KIAA0101 Hs.81892 9768 15q22.31
25 TSPAN-1 Tetraspan 1 Hs.38972 10103 1p34.1
26 TDE2L Tumor differentially expressed 2-like Hs.270655 347735 1p35.1
27 AGR2 Anterior gradient 2 homolog (Xenopus laevis) Hs.530009 10551 7p21.3
28 ARHGAP27 Rho GTPase activating protein 27 Hs.463165 201176 17q21.31
29 NMES1 Normal mucosa of esophagus specific 1 Hs.112242 84419 15q21.1
30 CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 1 Hs.512682 634 19q13.2
31 ST14 Suppression of tumorigenicity 14 (colon carcinoma, matriptase, epithin) Hs.504315 6768 11q24-q25
32 LOC387882 hypothetical protein Hs.525657 387882 12q23.3
33 TRPM4 Transient receptor potential cation channel, subfamily M, member 4 Hs.467101 54795 19q13.33
34 BCLP Beta-casein-like protein Hs.534521 113452 1p35-p34
35 IFI30 Interferon, gamma-inducible protein 30 Hs.14623 10437 19p13.1
36 ABP1 Amiloride binding protein 1 (amine oxidase (copper-containing)) Hs.521296 26 7q34-q36
37 ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 Hs.306251 2065 12q13
38 MAL2 Mal, T-cell differentiation protein 2 Hs.201083 114569 8q24.12
39 CDH17 Cadherin 17, LI cadherin (liver-intestine) Hs.89436 1015 8q22.1
40 CDH1 Cadherin 1, type 1, E-cadherin (epithelial) Hs.461086 999 16q22.1
(B) Downregulated
1 Similar to lymphocyte antigen 6 complex, locus G5B; G5b protein Hs.23650 112476 16p11.2
2 RARRES2 Retinoic acid receptor responder (tazarotene induced) 2 (TIG2) Hs.521286 5919 7q36.1
3 PDGFD Platelet derived growth factor D Hs.352298 80310 11q22.3
4 Hypothetical protein MGC1136 Hs.8719 78986 8p12
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Figure 2 Semi-quantitative RT–PCR analysis of RNA expression in
normal ovaries (n¼2), mucinous borderline tumours (n¼3), mucinous
ovarian cancers (n¼3) and serous ovarian cancers (n¼3). RT-, no reverse
transcriptase control; water, no cDNA. For gene descriptions, see Table 2
and Supplementary Data.
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sFigure 3A). Moreover, LGALS4 is located at 19q13.3, a region
associated with a high frequency of loss of heterozygosity in MOC
(Feltmate et al, 2005) and where we identified a cluster of
upregulated genes. We therefore examined the expression of
LGALS4 in ovarian carcinoma using immunohistochemistry
(Table 1, Figure 3B). In accordance with the transcript profiling
results, expression of LGALS4 was highly and specifically
expressed in MOC (median expression 72% of cells staining
positive) compared to the other ovarian carcinoma subtypes
(serous and endometroid, Po0.001; clear cell P¼0.002) and to
normal ovarian surface epithelium (P¼0.002), all of which had a
median expression equivalent to zero (Figure 4A). To identify if
LGALS4 expression occurs early in disease onset, we examined its
expression in benign mucinous cysts and mucinous borderline
tumours, in addition to low- and high-stage MOC. LGALS4
expression was detected at a median expression level of
approximately 30% of cells staining in benign mucinous cysts,
increasing in borderline tumours to similar levels of expression
as in MOC (470% of cells; Figure 4B). There was no significant
difference in expression between borderline tumours and low
grade MOC (P¼0.47), and although a decrease in expression from
low- to high-stage MOC was observed, this was not statistically
significant (P¼0.21). Statistical analysis did not reveal any
correlation between LGALS4 expression and clinicopathological
parameters (age, grade, stage, outcome; Table 1) in the ovarian
mucinous tumour cohort (data not shown).
DISCUSSION
Mucinous ovarian cancers are one of the less common histological
subtypes of ovarian carcinoma. Combined with the difficulty in
accurate diagnosis of primary disease, its relative rarity has
contributed to the lack of knowledge regarding the molecular basis
Table 4 Selected categories/genes from Gene Ontology (GO) analysis of genes specifically upregulated in MOC compared to other histological subtypes
of ovarian cancer
Rank Symbol Name Locus link
Biological process
Cell adhesion
1 LGALS4 Lectin, galactoside-binding, soluble, 4 (galectin 4) 3960
6 CDH17 Cadherin 17, LI cadherin (liver-intestine) 1015
11 CEACAM5 CEA-related cell adhesion molecule 5 (CEA) 1048
61 CEACAM6 CEA-related cell adhesion molecule 6 4680
Cell signalling
103 MST1R Macrophage stimulating 1 receptor (c-met-related tyrosine kinase) (RON) 4486
113 PTK6 PTK6 protein tyrosine kinase 6; breast tumor kinase BRK 5753
Proliferation
43 TM4SF4 Transmembrane 4 superfamily member 4 7104
72 TM4SF5 Transmembrane 4 superfamily member 5 9032
103 MST1R Macrophage stimulating 1 receptor (c-met-related tyrosine kinase) (RON) 4486
122 TM4SF3 Transmembrane 4 superfamily member 3 7103
Apoptosis
17 BCL2L14 BCL2-like 14 (apoptosis facilitator) 79370
Molecular function
Mucins
4 MUCDHL Mucin and cadherin-like 53841
8 MUC13 Mucin 13, epithelial transmembrane 56667
10 MUC3B Mucin 3A, intestinal NA
15 MUCDHL Mucin and cadherin-like 53841
44 MUC17 Mucin 17 140453
51 MUC2 Mucin 2, intestinal/tracheal 4583
Carbohydrate metabolism
54 TFF1 Trefoil factor 1 (breast cancer, estrogen-inducible sequence) 7031
59 FUT3 Fucosyltransferase 3 (galactoside 3(4)-L-Fucosyltransferase, Lewis blood group) 2525
74 SI Sucrase-isomaltase (alpha-glucosidase) 6476
85 GCNT3 Glucosaminyl (N-acetyl) transferase 3, mucin type 9245
Protein glycosylation
32 UGT1A9 UDP glycosyltransferase 1 family, polypeptide A9 54600
59 FUT3 Fucosyltransferase 3 (galactoside 3(4)-L-Fucosyltransferase, Lewis blood group) 2525
79 FBP1 Fructose-1,6-bisphosphatase 1 2203
85 GCNT3 Glucosaminyl (N-acetyl) transferase 3, mucin type 9245
Protein hydrolysis
7 MEP1A Meprin A, alpha (PABA peptide hydrolase) 4224
Transcription factors
26 CDX1 Caudal type homeo box transcription factor 1 1044
46 HNF4A Hepatocyte nuclear factor 4, alpha 3172
135 CDX2 Caudal type homeo box transcription factor 2 1045
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sof its development and progression. In this study, we have shown
that MOC show a gene expression profile that both overlaps with
and is distinct from the other histological subtypes of ovarian
carcinoma, presumably reflecting their common ovarian origin but
different morphological and clinical presentations. In particular,
we found that MOC express genes that underlie their morpho-
logical phenotype, including intestinal-specific genes, which likely
reflects the intestinal-type differentiation characteristic of most
MOC (Feeley and Wells, 2001). A variety of mucin molecules are
also expressed in MOC. Alterations in expression of mucins,
including loss of organ specificity, are a common feature of cancer
and are associated with altered biological properties including
metastatic potential (Byrd and Bresalier, 2004). In addition,
variations in mucin glycosylation patterns can cause changes in
tumour cell adhesion, migration and invasion (Casey et al, 2003),
and can be mediated by the differential expression of glycosylation
enzymes including fucosyltransferases and sialyltransferases.
We identified several such enzymes, suggesting specific mucin
glycosylation patterns are a feature of MOC.
It is likely that many carcinomas diagnosed as primary
mucinous ovarian cancer are more likely to be metastatic disease
originating in the gastrointestinal tract (Gilks, 2004; Seidman et al,
2004). In this study, we were particularly careful to only include
patients that clearly fit with current clinical and histological
guidelines as primary MOC rather than metastatic disease (Seid-
man et al, 2003; Hart, 2005). However, these strict selection
criteria, combined with the relative rarity of MOC, resulted in a
small sample number both for the transcript profiling and
validation experiments. In addition, although comprising at least
75% tumour cells, the tissue samples used in the transcript
profiling experiments were not microdissected and therefore may
contain a small proportion of stromal elements. Therefore, our
results remain to be validated in independent studies. To this end,
several published studies have reported similar findings in regard
to the genetic profile of MOC. First, Schwartz et al (2002) used
principal components analysis to show that gene expression
profiles could distinguish MOC from serous ovarian cancer, with
some overlap with endometrioid ovarian cancer. Secondly, using
cDNA arrays incorporating 9121 elements, Ono et al (2000)
identified 115 genes that were differentially regulated between
serous ovarian carcinomas and MOC). By comparing the Unigene/
Locus Link identifiers corresponding to the GenBank accessions in
the Ono study to the gene identifiers in our study (Table 2 and
Supplementary Data), we identified only one gene (TUBB2; tubulin
beta 2) that overlaps between our lists of differentially expressed
genes. A more recent study reported 46 genes that were
overexpressed in MOC compared to the other histological subtypes
of ovarian carcinoma and to normal ovarian surface epithelium
(Marquez et al, 2005). Fifteen of those genes (TM4SF3, S100P,
TM4SF4, CEACAM6, LGALS4, CEACAM5, TUBB, CTSE, GCNT3,
REG4, FABP1, SDCBP2, TFF1, RNF128, PLAC8) were also
identified in our study. Moreover, we also showed that LGALS4
is consistently highly expressed in MOC but is absent in the other
histological subtypes of ovarian cancer and normal ovaries using
immunohistochemistry, thus confirming the transcript profiling
results.
Progression from borderline tumours and low-stage carcinoma
to advanced MOC is associated with a poor outcome; hence the
identification of tumour markers that can detect early disease,
together with those that can predict patients likely to progress to
advanced stage MOC, would have a major impact on patient
prognosis. We determined that LGALS4 is not expressed in normal
ovarian surface epithelium but is expressed at high levels in
mucinous borderline tumours and in benign mucinous cysts,
consistent with activation of expression early in MOC develop-
ment. We did not identify any genes including LGALS4 that were
significantly differentially expressed between mucinous borderline
tumours and MOC, suggesting that there may be very few or only
subtle changes in gene expression between mucinous borderline
tumours and low-stage MOC (which were used in the transcript
profiling analysis), concordant with their similar outcomes. A
study with sufficient power to compare high-stage MOC to
borderline and low-stage MOC may reveal gene expression
changes that correlate with the poor prognosis in these patients.
There are currently no specific or sensitive serum markers for
the diagnosis of MOC (Rapkiewicz et al, 2004). MOC often fail to
express the ovarian cancer serum marker CA125 (MUC16), which
is frequently elevated in the serum of patients with nonmucinous
ovarian carcinoma. Although a cell surface adhesion molecule,
LGALS4 has at least a partial extracellular component (Huflejt and
Leffler, 2004), but to our knowledge there is no report of its
Borderline mucinous (n=4)
Borderline serous (n=3)
Endometrioid ovarian cancer (n=8)
Mucinous ovarian cancer (n=3)
Serous ovarian cancer (n=31)
Normal ovary (n=4)  
A
Mucinous Serous Normal B
2000
1500
1000
500
0
Figure 3 (A) mRNA transcript profile for LGALS4. The dashed line
represents the signal intensity of the 15th percentile of the gene expression
in normal body tissues (Henshall et al, 2003a); (B) representative
immunohistochemistry staining for LGALS4 in MOC, serous ovarian
cancer, normal ovarian surface epithelium (arrowed) and epithelial inclusion
cysts (inset);  40 magnification.
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Figure 4 Box plots showing distribution of expression of LGALS4 in (A)
normal ovarian surface epithelium (n¼14) and in different histological
subtypes of ovarian carcinoma: MOC (n¼10); endometrioid ovarian
cancer (n¼22); serous ovarian cancer (n¼55); clear cell ovarian cancer
(n¼8); and (B) in epithelial ovarian inclusion cysts (n¼8); benign
mucinous cysts (n¼8); mucinous borderline tumours (n¼29); low- (grade
1; n¼6) and high-grade (grade 2–3; n¼4) MOC; and low- (stage I; n¼5)
and high-stage MOC (stage II–III; n¼5). For explanation of box plots, see
Materials and Methods.
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spresence in serum. Serum antibodies against LGALS4 have,
however, been reported in a patient with colorectal cancer (Scanlan
et al, 1998). Given the high level of LGALS4 expression in MOC,
one might predict that similar antibodies could be detected in
patients with MOC, which is currently under investigation. Hence
LGALS4 may have application as an early serum diagnostic marker
of MOC, either alone or in combination with other markers such as
CEA (CEACAM5) and CA19.9 (Rapkiewicz et al, 2004; Hart, 2005).
In addition, the high level of LGALS4 expression in MOC may aid
in the histological differentiation of primary MOC from metastatic
ovarian carcinoma arising at other sites (Heinzelmann-Schwarz
et al; manuscript submitted for publication).
As previously suggested (Hess et al, 2004), the obvious genetic
similarities of MOC with mucinous-type intestinal carcinomas
support a move toward the use of a therapeutic approach tailored
to the molecular characteristics of MOC rather than the tissue of
origin. Patients with advanced stage MOC generally receive the
same adjuvant chemotherapy as the other subtypes of ovarian
carcinoma, normally a platinum-based approach combined with
paclitaxel. The poor survival associated with advanced MOC may
reflect a failure to respond to this regime (Hess et al, 2004). Hence,
alternative combination chemotherapy regimes that target both
the ovarian and mucinous intestinal genetic components of
MOC, such as a platin compound combined with 5-fluorouracil,
commonly used in the treatment of intestinal carcinomas, may
prove to be more efficacious for MOC. This, however, remains to
be tested in appropriate clinical trials.
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